ArticleCPT: pharmacometrics & systems pharmacology2026
A QSP Model of Valproic Acid Toxicity in Pediatric and Adult Populations: Implications for Formulation Selection and L-Carnitine Supplementation.
Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A QSP Model of Valproic Acid Toxicity in Pediatric and Adult Populations: Implications for Formulation Selection and L-Carnitine Supplementation.CPT: pharmacometrics & systems pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valproic acid (VPA), a widely prescribed short-chain fatty acid for managing epilepsy, psychiatric conditions, and migraines, offers significant therapeutic benefits despite its concerning toxicity profile. This study extends our previously developed Quantitative Systems Pharmacology (QSP) model by incorporating age, sex, and formulation-related covariates to characterize VPA-induced toxicity across diverse populations. We developed virtual populations representing four demographic groups: toddlers (0-2 years), children (2-14 years), women (14-40 years), and men (14-40 years). Age-appropriate dosing regimens were simulated: 35 mg/kg/day for toddlers, 25 mg/kg/day for children, and 15 mg/kg/day for adults. The model successfully predicted overall incidences of hyperammonemia (29%), hyperlipidemia (54%), and hepatotoxicity (2%), aligning with previously reported clinical data. Notably, our model revealed distinct age-dependent toxicity patterns, with significantly lower incidences in toddlers compared to similar profiles observed in children and adult women. Formulation comparison demonstrated that extended-release formulations showed consistent directional trends toward lower adverse effect incidences compared to delayed-release formulations across all endpoints. The model also quantitatively assessed L-carnitine supplementation (CS) benefits, suggesting that administering L-carnitine at twice the VPA dose (in mg) effectively prevents hyperammonemia and maintains physiological fatty acid levels. This work advances our understanding of VPA-induced toxicity mechanisms across populations and provides evidence-based recommendations for optimizing formulation selection and CS in both pediatric and adult patients receiving VPA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.